Cardiac complications may result from high-dose chemotherapy or irradiation administered during the conditioning phase of bone marrow and blood stem cell transplantation (BMT). To assess the frequency of clinically serious cardiac toxicity related to the acute phase of BMT, we retrospectively examined life-threatening or fatal cardiotoxicity identified using the complications records of our transplant center clinical database. All serious cardiac toxicity events within 100 days of BMT except those attributable to septic shock, pneumonitis or multi-organ failure were reviewed. Of 2821 BMT patients at the University of Minnesota between 1977 and 1997, 26 were identified as having suffered major or fatal (n = 13) cardiotoxicity (0.9%, 19 adults and seven children). Rapidly progressive heart failure resulted in death of 11 patients, one patient had fatal pericardial tamponade, and one had an acute ventricular fibrillation arrest. The remaining 13 patients (50%) had lifethreatening cardiotoxicity including four patients with pericardial tamponade and nine patients with cardiac arrhythmias. Overall, we observed that acute, major cardiotoxic events attributable to BMT are uncommon, occurring with a frequency of Ͻ1%. These data suggest that with appropriate pre-transplant clinical evaluation, high-dose cyclophosphamide and irradiation in the BMT preparative phase does not result in frequent, clinically relevant short-term cardiac toxicity. Bone Marrow Transplantation (2001) 28, 283-287.
Several other cytotoxic drugs such as busulfan, carmustine or cytarabine used in pre-BMT regimens may cause significant cardiotoxicity. [4] [5] [6] Acute myocardial infarction and various cardiac arrhythmias including cardiac arrest as a consequence of infusion of cryopreserved marrow have been reported during the acute phase of BMT. 7 Pretreatment with anti-tumor antibiotics including anthracyclines and prior mediastinal irradiation may increase the risks of adverse cardiac sequelae after BMT, but identification of the risk factors and effective strategies for cardiologic prescreening have not been well established. 4 Although cardiac complications associated with BMT have been documented in several series, the incidence of reported cardiotoxicity has varied among investigators, probably reflecting patient selection, differences in BMT preparative regimens and lack of universal grading system for cardiotoxic events. 4, 8 To assess the frequency and degree of clinically serious cardiac toxicity related to the acute phase of BMT, we examined all cases of life-threatening or fatal cardiotoxicity using the prospectively collected computerized database of our transplant center.
Materials and methods
The University of Minnesota BMT database contains prospectively collected data on all patients transplanted at our center. Database records on all patients receiving a blood or marrow transplant between 1 January 1977 and 1 September 1997 were screened for any circulatory event entry. These 2821 patients (1631 males, 58%) were a median of 22 years old (range 0.6-67) at transplant and 1257 (45%) received a related donor allograft, 592 (21%) an unrelated donor graft and 972 (34%) an autograft. Two hundred and five (73%) received total body irradiation, 111 (4%) total lymphoid irradiation (plus chemotherapy) in their pre-BMT conditioning and 659 (23%) received chemotherapy agents only. Patients with circulatory events (n = 842) were identified and 628 events occurring within the first 100 days post transplant were evaluated. For these patients, all available medical records, notes, correspondence and autopsy reports were reviewed to identify, in detail, the nature of the event and/or prior cardiac disease or its evolution.
We collected additional data including specific doses of previous anthracycline therapy or mediastinal radiation. Where no original flowsheets or clinic notes regarding the dose of administered anthracyclines or radiotherapy could be found, the drug dose was estimated based on the known duration of treatment (number of cycles) with the specified anthracycline-containing chemotherapy protocols. The cumulative dose of pre-BMT anthracycline exposure was then categorized as none, low (0-99 mg/m 2 ), medium (100-399 mg/m 2 ) and high (Ͼ400 mg/m 2 ). The cumulative dose of anti-tumor antibiotics given as doxorubicin, daunorubicin, idarubicin and mitoxantrone was calculated using previously reported maximum cumulative doses above which the probability of cardiotoxicity is high. These upper limit cumulative doses were 150 mg/m 2 for idarubicin 9 and 160 mg/m 2 for mitoxantrone, 10 which was compared to a generally accepted safe upper limit, cumulative dose of doxorubicin of 450 mg/m 2 . Therefore, the actual cumulative dose of idarubicin was multiplied by 3.0, and that of mitoxantrone by 2.8, to obtain a doxorubicin equivalent anthracycline dose. For daunorubicin conversion, doxorubicin is computed as two-thirds of the daunorubicin dose with respect to cardiotoxicity. 8, 11 For the entire database cohort, specific details of pre-BMT cardiac disease, pre-BMT anti-tumor antibiotic dosing or thoracic irradiation were unavailable, thus precluding a formal risk factor analysis for post-BMT cardiac events.
All cardiac events were reviewed and categorized using previously published grading systems for cardiac toxicity after BMT. 4, 12 This scale scores grade I as: (1) cardiomegaly on chest X-ray without symptoms, (2) mild ECG changes not requiring treatment, (3) asymptomatic pericardial effusion; grade II as (1) moderate ECG changes requiring and responding to medical intervention, (2) congestive heart failure requiring and responding to afterload reduction, diuretics and digitalis, (3) pericarditis; grade III as (1) severe ECG abnormalities with no or only partial response to medical intervention, (2) congestive heart failure requiring inotropic support, (3) cardiogenic shock, (4) decrease in QRS voltage by Ͼ50%, (5) pericardial tamponade; and grade IV as fatal toxicity.
For this analysis we included lethal toxicity defined as death from any cardiovascular cause (grade IV) and major toxicity including occurrence of clinical congestive heart failure requiring pressor or inotropic support, cardiac tamponade or severe EKG abnormalities (grade III). Less severe cardiac toxicity (grades I and II) was noted, but the incidence of these lesser events could not be reliably determined on retrospective review. These minor episodes might have been underreported and thus were excluded from this analysis of serious cardiac events. Other events (n = 602) were excluded if record review identified alternate, non-cardiac events including sepsis (n = 56), capillary leak syndrome (n = 23), lung injury (n = 16), hypertension (n = 256), hypotension (n = 19), thromboembolism (n = 26), renal failure (n = 7), multiorgan failure (n = 20), infectious or malignant invasion of the heart (n = 41) and other, non-cardiac events (n = 30). Grade I-II, mild and transient heart failure or fluid overload (n = 20), self-limiting arrhythmias (n = 25), or pericarditis (n = 63) were also excluded.
Results
This detailed review identified 26 BMT patients who experienced grade III or IV primary cardiac toxicity during the first 100 days post-BMT (Table 1 ). The frequency of such serious cardiac complications is 26 of 2821 receiving BMT (0.9%). The clinical characteristics of these 26 patients are shown in Table 2 . Nineteen were adults and seven were children (median age, 35 years, range 5-62 years). Fifteen were male. Allogeneic BMT was performed in 16 cases, autologous in seven, and no BMT in three cases (ie cardiac toxicity occurred during pre-BMT conditioning and precluded the infusion of marrow or stem cells). The most frequently used conditioning regimen was cyclophosphamide and TBI (14 cases; 54%).
As shown in Table 2 , 13 patients (50%) had fatal cardiotoxicity (heart failure resulted in death of 11 patients, one patient had fatal pericardial tamponade, and another one a ventricular fibrillation-arrest). Postmortem examinations were performed in eight of 13 patients and confirmed fatal cardiotoxicity (details in Table 2 ). In three patients who died of acute cardiomyopathy, autopsy showed diffuse intramyocardial hemorrhage characteristic of cyclophosphamide toxicity in two and chronic chemotherapy myocardiopathy in the third.
Nine of 11 cases of fatal heart failure occurred early in the course of BMT (day −6 to +12 post BMT). Of these, only three had subnormal pre-transplant left ventricular ejection fraction (EF) (45%, 39%, 39%). The other eight patients had normal (Ͼ50%) pretransplant EF and displayed no clinical signs or symptoms of cardiac compromise on pretransplant screening. Four of 13 patients with fatal cardiotoxicity related to the conditioning phase of BMT had high pretransplant anthracycline exposure, and two of these four had received prior mediastinal irradiation in addition. Only one patient with lethal heart failure had all three risk factors including higher anthracycline exposure and prior mediastinal irradiation, as well as subnormal EF pretransplant.
The remaining 13 patients (50%) had life-threatening cardiotoxicity, which included four patients with pericardial tamponade requiring pericardiocentesis, and nine patients with cardiac arrhythmias. These included symptomatic and/or hemodynamically significant atrial fibrillation/flutter requiring electrical cardioversion in six patients Table 1 Major cardiac toxicity before day +100 post BMT Including atrial fibrillation/flutter (n = 6, one associated with acute myocardial infarction; recurrence of pre-BMT atrial fibrillation in three other cases), asystole arrest (n = 1), cardiac arrest immediately post marrow infusion (n = 1) and a ventricular fibrillation arrest (n = 2, one fatal). showed heart without significant lesions Cumulative pre-BMT anthracycline (or equivalent anti-tumor antibiotic) therapy: none (0), 0 mg/m 2 ; low (+), 1-99 mg/m 2 ; medium (++), 100-399 mg/m 2 ; high (+++), Ͼ400 mg/m 2 . AA = aplastic anemia; AFib = atrial fibrillation; ALL = acute lymphocytic leukemia; allo = allogeneic BMT; AML = acute myeloid leukemia; Ara-C = cytarabine; auto = autologous BMT; BCNU = carmustine; Bu = busulfan; CHF = congestive heart failure; CLL = chronic lymphocytic leukemia; CML = chronic myeloid leukemia; CPR = cardiopulmonary resuscitation; Cy = cyclophosphamide; HD = Hodgkin's disease; LVEF = left ventricular ejection fraction; MI = myocardial infarction; nd = not determined; nl = normal; NHL = non-Hodgkin's lymphoma; VM26 = teniposide; VP-16 = etoposide; TBI = total body irradiation; TLI = total lymphoid irradiation; XRT = irradiation.
(exacerbation of a previous arrhythmia in three cases) and an arrest secondary to ventricular fibrillation in one patient. Two other patients developed cardiac arrest with asystole (one occurring post marrow infusion) responding to cardiopulmonary resuscitation. Summarizing the whole group's cardiac risk factors, of the 26 patients, five had high pre-BMT anthracycline (equivalent) exposure, five had prior mediastinal irradiation and four had a resting LVEF Ͻ45%. Five had two of these risk factors and three patients had all three risk factors pre-BMT.
Discussion
The goal of the present study was to review the incidence and characterize serious acute cardiac toxicity developing after BMT. Using conventional pre-BMT clinical cardiac evaluation through history and physical examination along with assessment of resting LVEF by radionuclide ventriculography as screening methods, of 2821 BMT recipients, only 26 patients suffered life-threatening or lethal cardiac toxicity (0.9%) during the first 100 post-transplant days. The majority of fatal events were secondary to acute decompensated heart failure. Cardiac tamponade and cardiac arrhythmias were the most common life-threatening, but reversible events. Overall, we observed a remarkably low frequency of major cardiac events.
This low incidence of cardiac toxicity is comparable to previously reported, but smaller studies. In one report, clinically significant, major cardiotoxicity associated with BMT preparative regimen occurred in three of 170 patients (1.8%) evaluated prospectively. 8 In several other series, no serious or fatal acute cardiac toxicity was observed. 13 16, 17 Variability in grading the severity of BMT-associated cardiotoxicity may hamper the comparability as well. A standardized system has been proposed by Appelbaum 12 and further modified by Bearman et al. 4 However, using this system, frequent, clinically significant and potentially lifethreatening episodes of heart failure are classified as minor (grade II) solely because the use of inotropic agents could be avoided by administering diuretics and afterload reducers, the major effective tools for management of heart failure. 18 Therefore, using even these standardized cardiac toxicity criteria, clinically major heart failure may be underreported. Finally, even with detailed review, it is difficult in some cases to distinguish the cardiotoxic effects of the BMT conditioning regimen from the secondary cardiac and circulatory consequences of non-cardiac, lifethreatening events, including sepsis, pneumonitis or multiorgan failure syndrome.
In the current study, strict adherence to the published grading system for acute BMT-related cardiac toxicity resulted in exclusion of a number of significant episodes of heart failure, which were manageable with diuretics, digitalis or afterload reducers. These grade II events were excluded by definition, as our concern was variable identification of these less serious events, confounding an accurate determination of their incidence. More serious events are more easily and reliably identified, both retrospectively and prospectively.
Although a formal risk factor analysis concerning pretransplant dose of cardiotoxic drugs, prior use of mediastinal irradiation and pretransplant LV function could not be performed in this study, there appeared to be no clear association between any of these parameters and the development of subsequent BMT-related cardiac toxicity. These risk factors have been studied previously with rather inconsistent results, especially when analyzing the utility of screening for decreased cardiac function as a predictor for subsequent cardiac complications. 4, 8, 15 The low frequency of serious events observed in this study suggest, albeit indirectly, that pre-BMT clinical evaluation including a detailed history, physical examination, chest X-ray and resting EKG to identify patients with clinically manifest poorly controlled heart failure, unstable angina or arrhythmia may be a sufficient screening tool to recognize potential candidates for BMT at high risk for BMT-associated cardiac complications. 8 
